Cuervo Guillermo, Camoez Mariana, Shaw Evelyn, Dominguez María Ángeles, Gasch Oriol, Padilla Belén, Pintado Vicente, Almirante Benito, Molina José, López-Medrano Francisco, Ruiz de Gopegui Enrique, Martinez José A, Bereciartua Elena, Rodriguez-Lopez Fernando, Fernandez-Mazarrasa Carlos, Goenaga Miguel Ángel, Benito Natividad, Rodriguez-Baño Jesús, Espejo Elena, Pujol Miquel
Department of Infectious Diseases, Hospital Universitari de Bellvitge; Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Microbiology, H. Bellvitge, Barcelona, Spain.
BMC Infect Dis. 2015 Oct 30;15:484. doi: 10.1186/s12879-015-1227-y.
The aim of the study was to determine clinical and microbiological differences between patients with methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia (CRB) undergoing or not undergoing haemodialysis, and to compare outcomes.
Prospective multicentre study conducted at 21 Spanish hospitals of patients with MRSA bacteraemia diagnosed between June 2008 and December 2009. Patients with MRSA-CRB were selected. Data of patients on haemodialysis (HD-CRB) and those not on haemodialysis (non-HD-CRB) were compared.
Among 579 episodes of MRSA bacteraemia, 218 (37.7%) were CRB. Thirty-four (15.6%) were HD-CRB and 184 (84.4%) non-HD-CRB. All HD-CRB patients acquired the infection at dialysis centres, while in 85.3% of the non-HD-CRB group the infection was nosocomial (p < .001). There were no differences in age, gender or severity of bacteraemia (Pitt score); comorbidities (Charlson score ≥ 4) were higher in the HD-CRB group than in the non-HD-CRB group (73.5% vs. 46.2%, p = .003). Although there were no differences in VAN-MIC ≥ 1.5 mg/L according to microdilution, using the E-test a higher rate of VAN-MIC ≥ 1.5 mg/L was observed in HD-CRB than in non-HD-CRB patients (63.3% vs. 44.1%, p = .051). Vancomycin was more frequently administered in the HD-CRB group than in the non-HD-CRB group (82.3% vs. 42.4%, p = <.001) and therefore the appropriate empirical therapy was significantly higher in HD-CRB group (91.2% vs. 73.9%, p = .029). There were no differences with regard to catheter removal (79.4% vs. 84.2%, p = .555, respectively). No significant differences in mortality rate were observed between both groups (Overall mortality: 11.8% vs. 27.2%, p = .081, respectively), but there was a trend towards a higher recurrence rate in HD-CRB group (8.8% vs. 2.2%, p = .076).
In our multicentre study, ambulatory patients in chronic haemodialysis represented a significant proportion of cases of MRSA catheter-related bacteraemia. Although haemodialysis patients with MRSA catheter-related bacteraemia had significantly more comorbidities and higher proportion of strains with reduced vancomycin susceptibility than non-haemodialysis patients, overall mortality between both groups was similar.
本研究旨在确定接受或未接受血液透析的耐甲氧西林金黄色葡萄球菌(MRSA)导管相关菌血症(CRB)患者的临床和微生物学差异,并比较其预后。
在21家西班牙医院进行的前瞻性多中心研究,研究对象为2008年6月至2009年12月期间诊断为MRSA菌血症的患者。选取MRSA-CRB患者,比较血液透析患者(HD-CRB)和未进行血液透析患者(非HD-CRB)的数据。
在579例MRSA菌血症发作中,218例(37.7%)为CRB。34例(15.6%)为HD-CRB,184例(84.4%)为非HD-CRB。所有HD-CRB患者均在透析中心感染,而非HD-CRB组85.3%的感染为医院获得性感染(p<0.001)。两组患者的年龄、性别或菌血症严重程度(皮特评分)无差异;HD-CRB组的合并症(Charlson评分≥4)高于非HD-CRB组(73.5%对46.2%,p=0.0)。尽管根据微量稀释法,VAN-MIC≥1.5mg/L无差异,但使用E-test法观察到HD-CRB患者中VAN-MIC≥1.5mg/L的比例高于非HD-CRB患者(63.3%对44.1%,p=0.051)。HD-CRB组比非HD-CRB组更频繁地使用万古霉素(82.3%对42.4%,p<0.001),因此HD-CRB组适当的经验性治疗比例显著更高(91.2%对73.9%,p=0.029)。两组在拔除导管方面无差异(分别为79.4%对84.2%,p=0.555)。两组的死亡率无显著差异(总体死亡率:分别为11.8%对27.2%,p=0.081),但HD-CRB组有复发率更高的趋势(8.8%对2.2%,p=0.076)。
在我们的多中心研究中,慢性血液透析的非卧床患者占MRSA导管相关菌血症病例的很大比例。尽管与非血液透析患者相比,患有MRSA导管相关菌血症的血液透析患者合并症显著更多,万古霉素敏感性降低的菌株比例更高,但两组的总体死亡率相似。